GSK plc files 6-K

GSK plc announced that Blenrep has been approved in China for the treatment of relapsed or refractory multiple myeloma in adults who have received at least one prior line of therapy. This approval is based on data from the DREAMM-7 trial, which showed a 42% reduction in the risk of death and nearly tripled median progression-free survival for the Blenrep combination compared to a daratumumab-based triplet.